Literature DB >> 6721992

A simple test for acetylator phenotype using caffeine.

D M Grant, B K Tang, W Kalow.   

Abstract

A method is presented for the use of caffeine, in the forms commonly ingested by a large proportion of the world's population, to test for the clinically important acetylation polymorphism. Each of 146 subjects provided a spot sample of urine between 2 and 6 h after coffee, tea or cola soft drink consumption, and the molar ratio of 5-acetylamino-6- formylamino -3-methyluracil ( AFMU ) to 1-methylxanthine (1X) was determined by a simple h.p.l.c. assay. The ratio afforded segregation of three apparent modes of acetylation capacity in this population, in concordance with a standard sulphamethazine phenotyping procedure and with other methods using controlled caffeine intake and urine collections. The day-to-day consistency of the method was established in eight selected subjects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721992      PMCID: PMC1463406          DOI: 10.1111/j.1365-2125.1984.tb02372.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  A filter paper method for determining isoniazid acetylator phenotype.

Authors:  W W Weber; W Brenner
Journal:  Am J Hum Genet       Date:  1974-07       Impact factor: 11.025

2.  Variability in caffeine metabolism.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

3.  A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report.

Authors:  E J Lee; L K Lee
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

4.  Kinetic discrimination of three sulfamethazine acetylation phenotypes.

Authors:  D J Chapron; P A Kramer; S A Mercik
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

5.  Clinical consequences of polymorphic acetylation of basic drugs.

Authors:  D E Drayer; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

6.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

7.  Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer.

Authors:  R A Cartwright; R W Glashan; H J Rogers; R A Ahmad; D Barham-Hall; E Higgins; M A Kahn
Journal:  Lancet       Date:  1982-10-16       Impact factor: 79.321

8.  Screening methods using sulfamethazine for determining acetylator phenotype.

Authors:  P du Souich; A J McLean; K Stoeckel; D Ohlendorf; M Gibaldi
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

9.  Polymorphic N-acetylation of a caffeine metabolite.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

10.  Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines.

Authors:  H Wolf; G M Lower; G T Bryan
Journal:  Scand J Urol Nephrol       Date:  1980
View more
  44 in total

1.  N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.

Authors:  S P Spielberg
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

2.  Exposure related mutagens in urine of rubber workers associated with inhalable particulate and dermal exposure.

Authors:  R Vermeulen; R P Bos; J Pertijs; H Kromhout
Journal:  Occup Environ Med       Date:  2003-02       Impact factor: 4.402

3.  Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.

Authors:  T Graf; F Broly; F Hoffmann; M Probst; U A Meyer; H Howald
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Detoxification pathways in the liver.

Authors:  D M Grant
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

5.  Host factors in occupational diisocyanate asthma: a Swiss longitudinal study.

Authors:  M Berode; M Jost; M Ruegger; H Savolainen
Journal:  Int Arch Occup Environ Health       Date:  2005-02-16       Impact factor: 3.015

Review 6.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

7.  BJCP 40th anniversary: moving forward, looking back.

Authors:  Annette Gilchrist; Yoon K Loke; Andrew A Somogyi; Adam F Cohen; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

8.  NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.

Authors:  A Nyéki; T Buclin; J Biollaz; L A Decosterd
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

Review 9.  Familial and genetic risk of transitional cell carcinoma of the urinary tract.

Authors:  Christine M Mueller; Neil Caporaso; Mark H Greene
Journal:  Urol Oncol       Date:  2008-06-18       Impact factor: 3.498

10.  Induction of P-450 in workers exposed to dioxin.

Authors:  W Halperin; W Kalow; M H Sweeney; B K Tang; M Fingerhut; B Timpkins; K Wille
Journal:  Occup Environ Med       Date:  1995-02       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.